TrialCNS drugs2019

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

Jeremy Hobart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.